Sort by

Send to

Choose Destination

Search results

Items: 5


VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens.

Sun N, Petiwala S, Lu C, Hutti JE, Hu M, Hu M, Domanus MH, Mitra D, Addo SN, Miller CP, Chung N.

CRISPR J. 2019 Aug;2:230-245. doi: 10.1089/crispr.2019.0018.


Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.

Jakob CG, Upadhyay AK, Donner PL, Nicholl E, Addo SN, Qiu W, Ling C, Gopalakrishnan SM, Torrent M, Cepa SP, Shanley J, Shoemaker AR, Sun CC, Vasudevan A, Woller KR, Shotwell JB, Shaw B, Bian Z, Hutti JE.

J Med Chem. 2018 Aug 9;61(15):6647-6657. doi: 10.1021/acs.jmedchem.8b00305. Epub 2018 Jul 30.


Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.

Das SG, Doshi JM, Tian D, Addo SN, Srinivasan B, Hermanson DL, Xing C.

J Med Chem. 2009 Oct 8;52(19):5937-49. doi: 10.1021/jm9005059.


Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.

Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, Al-Mousa F, Michelangeli F, Thomas DD, Lebien TW, Xing C.

Mol Pharmacol. 2009 Sep;76(3):667-78. doi: 10.1124/mol.109.055830. Epub 2009 Jun 26.


WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth.

Wang L, Sloper DT, Addo SN, Tian D, Slaton JW, Xing C.

Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.

Supplemental Content

Support Center